Abstract Details

Title Clinical Characteristics and Outcomes Among NARCOMS Registry Participants Treated With Alemtuzumab

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-087

Objective Describe the demographic/clinical characteristics and employment status of persons with MS who received alemtuzumab and participate in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.

Background Alemtuzumab is approved in >70 countries for treatment of adults with RRMS. Real-world data on alemtuzumab-treated patients are limited.

Design/Methods NARCOMS participants who started alemtuzumab and completed a follow-up survey 1 year later were queried from semi-annual update surveys between 2014 and 2017. Demographic/clinical characteristics were reported at alemtuzumab initiation and 1 year later, including disability level using the Patient-Determined Disease Steps (PDDS) and Performance Scales (PS).

Results Fifty NARCOMS participants reported initiating alemtuzumab and completed the 1-year survey (75.5% female; 78.0% Caucasian). Mean (SD) age at alemtuzumab initiation was 40.4 (10.1) years; mean age at symptom onset was 28.3 (8.0) years; and mean age at diagnosis was 33.8 (9.0) years. Most had RRMS (48%) or SPMS (28%), with others reporting “unsure/other” (22%) or PPMS (2%). Mean disease duration was 18.6 (10.2) years; 26% reported comorbidities. At alemtuzumab initiation, 68% had at least moderate disability on PDDS (level 4: Early Cane), and 86% had mild/greater fatigue level on fatigue PS; 32% reported having a relapse treated with steroids before alemtuzumab. At 1 year, 26%/56% had improved/stable PDDS; 22%/60% had improved/stable fatigue PS, and 18% had worsened fatigue; 18% reported having a relapse treated with steroids during Year 1 after alemtuzumab. Of those employed at alemtuzumab initiation, 100% remained employed a year later.

Conclusions After initiating alemtuzumab, the majority of participants reported improved/stable PDDS and fatigue PS. All employed NARCOMS participants with 1 year of follow-up survey data remained employed. These data show a favorable real-world patient experience after 1 year of alemtuzumab treatment, supporting the positive outcomes shown in clinical trials; assessment after both alemtuzumab courses will further confirm these findings.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Robert J. Fox, MD, FAAN (Cleveland Clinic)	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria Biologica. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InnoCare Pharma. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Fox has received research support from National Institutes of Health. The institution of Dr. Fox has received research support from National MS Society. Dr. Fox has received publishing royalties from a publication relating to health care.
Lobat Hashemi	No disclosure on file
	No disclosure on file
Thomas Carattini	No disclosure on file
	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.

��ɫ��

��ɫ��